ImmunOs Therapeutics AG
http://immunostherapeutics.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ImmunOs Therapeutics AG
Finance Watch: Venture Floodgates Open With New Funds, Dozens Of Rounds
Private Company Edition: While the tough state of financing for publicly traded drug developers continues, venture capital firms and private biopharma companies revealed billions of dollars in new VC funds and start-up financings, including $100m-plus mega-rounds for Tessa, Alladapt and ImCheck.
ImmunOs Gets Cash Injection To Advance Potential First-In-Class Cancer Agent
It has proved tricky of late for European biotechs to raise funds, but Switzerland's ImmunOs has gathered a group of top-tier US and European investors to help push lead asset IOS-1002, a first-in-class, multi-functional agent based on a naturally occurring human leukocyte antigen, towards the clinic.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice